丝裂原活化蛋白激酶激酶抑制剂相关视网膜病变1例_Chinese Journal of Ocular Fundus Diseases

Authors：

杜冬菊 ^1,2 , 刘思唯 ¹ , 崔金利 ¹ , 刘欣雨 ¹ , 何嘉萱 ¹ , 刘泽浩 ¹ ,  林英 ¹

1. ;
2. ;

Corresponding author：

林英, Email: linying@gzzoc.com

Keywords：

妥拉美替尼; 丝裂原活化蛋白激酶激酶抑制剂相关性视网膜病变; 浆液性神经上皮层脱离; 病例报告

DOI：

10.3760/cma.j.cn511434-20250724-00321

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

1.	Liu Y, Cheng Y, Huang G, et al. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor[J/OL]. Front Pharmacol, 2023, 14: 1271268[2023-09-21]. https://pubmed.ncbi.nlm.nih.gov/37808191/. DOI: 10.3389/fphar.2023.1271268.
2.	Keam SJ. Tunlametinib: first approval[J]. Drugs, 2024, 84(8): 1005-1010. DOI: 10.1007/s40265-024-02072-x.
3.	Stjepanovic N, Velazquez-Martin J, Bedard P. Ocular toxicities of MEK inhibitors and other targeted therapies[J]. Ann Oncol, 2016, 27(6): 998-1005. DOI: 10.1093/annonc/mdw100.
4.	Méndez-Martínez S, Calvo P, Ruiz-Moreno Ó, et al. Ocular adverse events associated with MEK inhibitors[J]. Retina, 2019, 39(8): 1435-1450. DOI: 10.1097/IAE.0000000000002451.
5.	Booth AEC, Hopkins AM, Rowland A, et al. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy[J/OL]. Ther Adv Med Oncol, 2020, 12: 1758835920944359[2020-07-31]. https://pubmed.ncbi.nlm.nih.gov/32821295/. DOI: 10.1177/1758835920944359.
6.	Francis JH, Habib LA, Abramson DH, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy[J]. Ophthalmology, 2017, 124(12): 1788-1798. DOI: 10.1016/j.ophtha.2017.05.038.
7.	Arora S, Surakiatchanukul T, Arora T, et al. Retinal toxicities of systemic anticancer drugs[J]. Surv Ophthalmol, 2022, 67(1): 97-148. DOI: 10.1016/j.survophthal.2021.05.007.
8.	Ucan Gunduz G, Gullulu ZZ, Nizam Tekcan S, et al. A case report and literature review of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib and trametinib: 4-year follow-up using retinal multimodal imaging[J]. Ocul Immunol Inflamm, 2024, 32(10): 2589-2593. DOI: 10.1080/09273948.2024.2401626.
9.	Wei X, Zou Z, Zhang W, et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma[J/OL]. Eur J Cancer, 2024, 202: 114008[2024-04-11]. https://pubmed.ncbi.nlm.nih.gov/38479118/. DOI: 10.1016/j.ejca.2024.114008.
10.	Shi Y, Han X, Zhao Q, et al. Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study[J/OL]. Exp Hematol Oncol, 2024, 13(1): 60[2024-06-12]. https://pubmed.ncbi.nlm.nih.gov/38867257/. DOI: 10.1186/s40164-024-00528-0.
11.	Hecquet C, Lefevre G, Valtink M, et al. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation[J]. Invest Ophthalmol Vis Sci, 2002, 43(9): 3091-3098.

1. Liu Y, Cheng Y, Huang G, et al. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor[J/OL]. Front Pharmacol, 2023, 14: 1271268[2023-09-21]. https://pubmed.ncbi.nlm.nih.gov/37808191/. DOI: 10.3389/fphar.2023.1271268.
2. Keam SJ. Tunlametinib: first approval[J]. Drugs, 2024, 84(8): 1005-1010. DOI: 10.1007/s40265-024-02072-x.
3. Stjepanovic N, Velazquez-Martin J, Bedard P. Ocular toxicities of MEK inhibitors and other targeted therapies[J]. Ann Oncol, 2016, 27(6): 998-1005. DOI: 10.1093/annonc/mdw100.
4. Méndez-Martínez S, Calvo P, Ruiz-Moreno Ó, et al. Ocular adverse events associated with MEK inhibitors[J]. Retina, 2019, 39(8): 1435-1450. DOI: 10.1097/IAE.0000000000002451.
5. Booth AEC, Hopkins AM, Rowland A, et al. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy[J/OL]. Ther Adv Med Oncol, 2020, 12: 1758835920944359[2020-07-31]. https://pubmed.ncbi.nlm.nih.gov/32821295/. DOI: 10.1177/1758835920944359.
6. Francis JH, Habib LA, Abramson DH, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy[J]. Ophthalmology, 2017, 124(12): 1788-1798. DOI: 10.1016/j.ophtha.2017.05.038.
7. Arora S, Surakiatchanukul T, Arora T, et al. Retinal toxicities of systemic anticancer drugs[J]. Surv Ophthalmol, 2022, 67(1): 97-148. DOI: 10.1016/j.survophthal.2021.05.007.
8. Ucan Gunduz G, Gullulu ZZ, Nizam Tekcan S, et al. A case report and literature review of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib and trametinib: 4-year follow-up using retinal multimodal imaging[J]. Ocul Immunol Inflamm, 2024, 32(10): 2589-2593. DOI: 10.1080/09273948.2024.2401626.
9. Wei X, Zou Z, Zhang W, et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma[J/OL]. Eur J Cancer, 2024, 202: 114008[2024-04-11]. https://pubmed.ncbi.nlm.nih.gov/38479118/. DOI: 10.1016/j.ejca.2024.114008.
10. Shi Y, Han X, Zhao Q, et al. Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study[J/OL]. Exp Hematol Oncol, 2024, 13(1): 60[2024-06-12]. https://pubmed.ncbi.nlm.nih.gov/38867257/. DOI: 10.1186/s40164-024-00528-0.
11. Hecquet C, Lefevre G, Valtink M, et al. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation[J]. Invest Ophthalmol Vis Sci, 2002, 43(9): 3091-3098.

Chinese Journal of Ocular Fundus Diseases

Latest Articles丝裂原活化蛋白激酶激酶抑制剂相关视网膜病变1例

Abstract Full text Figures/Tables Video References Cited by

Format

Content